eligibility_summary
Eligible: adults (>18) with established autoimmune disease, KPS >80, life expectancy >3 months, Hgb >80 g/L, and no contraindications to blood cell collection. Exclude: other active diseases complicating assessment, uncontrolled bacterial/fungal/viral infection, HIV, active HBV/HCV, pregnant or nursing, systemic steroids within 1 week, prior failed CAR-T.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Combined cell therapy using fetal tissue–derived mesenchymal stem cells (fMSCs, biological cell therapy) plus 4th‑generation CAR‑T cells (4SCAR, lentiviral T‑cell gene therapy with inducible caspase‑9 safety switch). Mechanisms: 4SCAR‑T cells express scFv receptors to B‑cell (CD19) and plasma‑cell (BCMA) antigens (and potentially other B/plasma markers), triggering T‑cell activation to deplete autoreactive B cells and antibody‑producing plasma cells, lowering pathogenic autoantibodies. fMSCs provide immunomodulatory/immunosuppressive effects (trophic factor secretion, inflammation suppression, tolerance promotion) to synergize with CAR‑T and mitigate toxicity. Targets: B cells and plasma cells, pathways: CD19 and BCMA antigen recognition, T‑cell activation signaling, and MSC‑mediated immune regulation.